Digital Trials Digest, our quarterly newsletter
In three short years, decentralized clinical trials (DCTs) have turned skeptics into believers. Trial sponsors who were once hesitant are now embracing the DCT model—and for good reason. Today’s DCTs are addressing longstanding industry challenges, expanding access to patients and clinicians, increasing diversity, accelerating cohort recruitment, and improving retention.
When it comes to decentralized clinical trials (DCTs), the pharmaceutical industry finds itself at a crossroads.
For patients with rare, incurable, or life-threatening diseases, clinical trials can offer new hope. Cancer patients, specifically, are often highly motivated to participate in research, particularly when they have an advanced or treatment-resistant form of cancer. Find out how decentralized clinical trials reach patients in the comfort of their homes.
While there's broad agreement on the gap between white and non-white participation in clinical trial enrollment, the number of non-white patients enrolled in clinical trials for general population studies is still quite low. But why?
Digital instruments such as sensors and wearables are transforming the industry’s definition of accuracy in three measures: volume, practicality, and precision.
Expectations for the time it takes to complete a vaccine clinical trial have been radically raised by the mRNA vaccines’ successes.
Decentralized trials (DCTs) expand older adults’ access to trials, allowing them to participate at higher rates.
Digital transformation is reshaping nearly every industry, and clinical trials are no exception. As technology plays a bigger role in healthcare, patients are demanding more access to medical research. It’s not just patients who are asking for more: Medical professionals, researchers, and pharmaceutical companies all want to improve quality, efficiency, and access to clinical trials.
The use of real world data in clinical trials is a hot topic. Doctors, biotech and pharmaceutical companies alike point to the tremendous potential to leverage this data to improve health outcomes.
Virtual clinical trials aren’t just a buzzword—these research models are here to stay. In fact, the global market for virtual clinical trials is expected to reach $12.9 billion by 2030, according to Grand View Research.